NCT06178445: Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 24 planned
- Started
- 17 Apr 2024
- Primary completion
- Dec 2026
- Arms
- SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
- Results
- None posted
- 21 Dec 2023: Trial registered
- 17 Apr 2024: Trial started